Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy.
de With M, Hurkmans DP, Oomen-de Hoop E, Lalouti A, Bins S, El Bouazzaoui S, van Brakel M, Debets R, Aerts JGJV, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM. de With M, et al. Among authors: van brakel m. Cancers (Basel). 2021 Mar 18;13(6):1370. doi: 10.3390/cancers13061370. Cancers (Basel). 2021. PMID: 33803602 Free PMC article.
CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab.
Kunert A, Basak EA, Hurkmans DP, Balcioglu HE, Klaver Y, van Brakel M, Oostvogels AAM, Lamers CHJ, Bins S, Koolen SLW, van der Veldt AAM, Sleijfer S, Mathijssen RHJ, Aerts JGJV, Debets R. Kunert A, et al. Among authors: van brakel m, van der veldt aam. J Immunother Cancer. 2019 Jun 8;7(1):149. doi: 10.1186/s40425-019-0608-y. J Immunother Cancer. 2019. PMID: 31176366 Free PMC article.
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Hurkmans DP, Verdegaal EME, Hogan SA, de Wijn R, Hovestad L, van den Heuvel DMA, Ruijtenbeek R, Welters MJP, van Brakel M, Basak EA, Pinedo HM, Lamers CHJ, van de Werken HJG, Groten JP, Debets R, Levesque MP, Dummer R, Kapiteijn E, Mathijssen RHJ, Aerts JGJV, van der Burg SH. Hurkmans DP, et al. Among authors: van brakel m. J Immunother Cancer. 2020 Dec;8(2):e001607. doi: 10.1136/jitc-2020-001607. J Immunother Cancer. 2020. PMID: 33427690 Free PMC article.
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.
Rijnders M, Robbrecht DGJ, Oostvogels AAM, van Brakel M, Boormans JL, Aarts MJB, Balcioglu HE, Hamberg P, Voortman J, Westgeest HM, Lolkema MP, de Wit R, van der Veldt AAM, Debets R. Rijnders M, et al. Among authors: van brakel m. Cancer Immunol Immunother. 2023 Mar;72(3):759-767. doi: 10.1007/s00262-022-03250-0. Epub 2022 Aug 17. Cancer Immunol Immunother. 2023. PMID: 35976415 Free PMC article.
Gene Engineering T Cells with T-Cell Receptor for Adoptive Therapy.
Kortleve D, van Brakel M, Wijers R, Debets R, Hammerl D. Kortleve D, et al. Among authors: van brakel m. Methods Mol Biol. 2022;2453:209-229. doi: 10.1007/978-1-0716-2115-8_13. Methods Mol Biol. 2022. PMID: 35622329 Free PMC article.
24 results